May 2020 Newsletter

June 2, 2020
Published By 
Mike Splaine
Heading 6
Heading 5

Heading 4

Heading 3

Heading 2

Heading 1

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Help us find the new normal in research

COVID-19 may have closed Main Street, but the fight against Alzheimer’s and dementia continues.

As researchers develop reopening plans and “innovative solutions” for their trials, Recruitment Partners recognizes the need for the opinions of potential research volunteers to help form these plans. To collect such data, we are asking care communities to provide feedback through a 5 minute questionnaire to help us understand how the Covid-19 epidemic is affecting participation in Alzheimer’s and dementia research within their communities.  We are also seeking feedback from persons with Alzheimers or dementia and their family caregivers through a separate 10 minute questionnaire.

How can you help?

First, as a care community representative, please answer a few questions about your operations and thoughts on research during and after the Covid-19 crisis by clicking here or visiting our website at https://recruitmentpartnersllc.com/.

Second, pass the word to persons with dementia and their caregivers that their feedback now will help researchers plan and execute the best research possible during and beyond the current crisis. Individuals and families can access the survey at https://www.surveymonkey.com/r/BR3PCN3 or by visiting our website at https://recruitmentpartnersllc.com/.

Participation is anonymous and the results will be posted on our website at the close of the survey.

THANK YOU FOR YOUR PARTICIPATION!

The National Alliance for Caregiving (NAC) and AARP release “Caregiving in the U.S. 2020”

The 2020 update to the NAC research series on caregiving reveals an increase in the number of family caregivers in the U.S. Family caregivers now encompass more than one in five Americans. The study also reveals that family caregivers are in worse health compared to five years ago. As the demand for caregiving rises with an aging population, there is an opportunity for the public and private sectors to work together to develop solutions to support family caregivers and those under their care. Access the Executive Summary here, and access the full report here.

What’s Happening in the Alzheimer’s Field?

Please pass the flavonoids

A recent study evaluating the diets of 2,800 people for an average of 20 years points to a reduced risk of developing Alzheimer’s or a related dementia in those who had diets high in flavonoids, particularly from fruits, red wine, and tea.  Researchers point out this is not a direct cause-and-effect, as it may suggest that people who ingest higher amounts of flavonoids through fruits, red wine, and tea may have other healthy habits that reduce their risk. Nevertheless, replacing a few unhealthy snacks with a serving of fruit can only help.  Read more here.

Results of GERAS-US study show economic impact of early cognitive decline

Recently published Eli Lilly study highlights the importance of early diagnosis using standard tools to evaluate underlying pathology, not just a assessment of symptoms and progression, and  that that early treatment not only benefits the patient, but also the caregiver. Read more about the GERAS-US study here.

Seaweed based drug is approved for trials in U.S.

Green Valley Pharmaceuticals’ Alzheimer’s drug oligomannate, which is currently available to patients in China after successful clinical trials, has been given approval by the FDA to begin late-stage trials in the U.S.  Green Valley has planned a global trial which will enroll over 2,000 participants, of which some will take the experimental drug for a year, plus an additional 6 month extension. While the Covid crisis has currently delayed the start of the trial, Green Valley is optimistic the drug will have FDA approval for patient use in the U.S. by 2025. Read more here.

Who We Are & What We Do

Recruitment Partners’ mission is to increase education & access to Alzheimer’s research. We recognize the importance of partnering with the individual’s care providers to meaningfully and successfully engage them in research. We have experience working with adult day health centers & long term care communities to help individuals with AD and their caregivers learn more about the research available in their community, and build a bridge for participation. Join our network! Email us today!

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.